UNSPSC 51102865: Neomycin/polymyxin/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

UNSPSC 51102865 Neomycin/polymyxin/pramoxine is a Commodity code that in practice covers a narrow range of topical antibiotic and anesthetic combination preparations, though the recent state and local activity tagged to this code does not reflect purchases of the products nominally within its scope. The Illinois Department of Public Health's August 2026 award through the MMCAP Infuse cooperative purchasing consortium supplied oral antibiotics (Doxycycline and Ciprofloxacin), and Seminole County, Florida's June 2026 procurement targeted Naloxone and drug deactivation systems—neither matching the neomycin/polymyxin/pramoxine combination product family. State and local health departments and county health authorities appear to be the primary issuing bodies using codes in this category for pharmaceutical procurement, typically leveraging cooperative purchasing vehicles such as MMCAP to access pre-negotiated pricing on bulk pharmaceutical supplies.

Activity is geographically limited in the recent record, with solicitations appearing in Illinois and Florida only. The Illinois Department of Public Health's completed Invitation for Bid with Chartwell Rx LLC for $2,999,999.11 over three years (including renewal periods) represents the most substantial recent award, with an initial 12-month term and options for years 2 and 3. Seminole County's Invitation for Bid for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, due July 26, 2023, was posted June 30, 2026, indicating that this code may be receiving inconsistent or miscategorized tagging in state and local procurement systems. The mismatch between the code's nominal scope and the actual procurement activity suggests that firms pursuing pharmaceutical supply contracts should verify direct alignment with the specific products being sought rather than relying on UNSPSC categorization alone in this commodity family.